Risk of developing thromboembolic and/or pregnancy events and related deaths in patients with solid tumors and positive aPL vs those with solid tumor and negative aPL antibodies (n = 4 studies)
| Cancer type (no. of studies) . | No. of positive patients/patients with aPL antibodies (%) . | No. of patients with positive/negative aPL antibodies (%) . | RR (95% CI) . | |
|---|---|---|---|---|
| Thromboembolic/pregnancy events | ||||
| Lung (n = 2)24,45,53 | 51/147 (34.7) | 19/167 (11.4) | 3.8 (1.2-12.2) | |
| GU (n = 2)43,56 | 10/40 (25.0) | 27/94 (28.7) | 2.3 (0.11-47.9) | |
| Death due to thromboembolic events | ||||
| Lung (n = 1)53 | 36/84 (42.9) | 24/121 (19.8) | 2.1 (1.4-3.3) | |
| Cancer type (no. of studies) . | No. of positive patients/patients with aPL antibodies (%) . | No. of patients with positive/negative aPL antibodies (%) . | RR (95% CI) . | |
|---|---|---|---|---|
| Thromboembolic/pregnancy events | ||||
| Lung (n = 2)24,45,53 | 51/147 (34.7) | 19/167 (11.4) | 3.8 (1.2-12.2) | |
| GU (n = 2)43,56 | 10/40 (25.0) | 27/94 (28.7) | 2.3 (0.11-47.9) | |
| Death due to thromboembolic events | ||||
| Lung (n = 1)53 | 36/84 (42.9) | 24/121 (19.8) | 2.1 (1.4-3.3) | |